DXTM

Microbix Reports Results for Q3 Fiscal 2023

Retrieved on: 
Thursday, August 10, 2023
COGS, Ageing, QAP (Colombia), ERP, OTCQX, DXTM, Antigen, TSX, YTD, Clothing, Bank, Q3

MISSISSAUGA, Ontario, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, reports results for its third quarter and YTD fiscal 2023 ended June 30, 2023 (“Q3” and “YTD”), a period in which strong revenues were realized along with a fully-funded partnering of its drug asset Kinlytic® urokinase (“Kinlytic”).

Key Points: 
  • MISSISSAUGA, Ontario, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, reports results for its third quarter and YTD fiscal 2023 ended June 30, 2023 (“Q3” and “YTD”), a period in which strong revenues were realized along with a fully-funded partnering of its drug asset Kinlytic® urokinase (“Kinlytic”).
  • For the three months ending June 30, 2023 (“Q3”)
    Q3 revenue was $5,530,152, an increase of 10% from Q3 2022 revenues of $5,011,025.
  • Such IT systems start-up costs were heaviest in Q3, as Microbix drove toward a Q4 2023 “go-live” for its new ERP system.
  • Overall, Q3 sales led to an operating and net loss of $769,108 versus a Q3 2022 operating and net income of $638,502.

Microbix Reports Results for Q1 Fiscal 2023 Sales of $2.5 million, Net Loss of $1.3 million

Retrieved on: 
Thursday, February 9, 2023
OTCQX, Growth, TSX, Marginal cost, Antigen, DXTM, Ay Qap, Bank

Microbix remains well-capitalized and is targeting to continue increasing sales of its testing-related medical devices and ingredients, thereby growing sales, margins, and earnings.

Key Points: 
  • Microbix remains well-capitalized and is targeting to continue increasing sales of its testing-related medical devices and ingredients, thereby growing sales, margins, and earnings.
  • Q1 sales were $2.5 million, meaningfully below the past several quarters.
  • The resulting reduction in gross margin dollars created a meaningful net loss for Q1.
  • Overall, weaker sales led to an operating loss and net loss of $1,299,262 versus a Q1 2022 operating income and net income of $880,778.

Microbix Reports Record Sales for Fiscal 2022

Retrieved on: 
Thursday, December 22, 2022
Antigen, EBITDA, TSX, DXTM, Growth, OTCQX, Investment, Ay Qap, Q4, Pharmaceutical industry, Bank

MISSISSAUGA, Ontario, Dec. 22, 2022 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, reports results for its year and fourth quarter ended September 30, 2022 (“2022” and “Q4”), with record sales and continued positive net earnings, plus ongoing progress upon its strategic goal of increasing its capacity for medical devices production and, over time, to thereby grow sales, margins, and earnings.

Key Points: 
  • MISSISSAUGA, Ontario, Dec. 22, 2022 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, reports results for its year and fourth quarter ended September 30, 2022 (“2022” and “Q4”), with record sales and continued positive net earnings, plus ongoing progress upon its strategic goal of increasing its capacity for medical devices production and, over time, to thereby grow sales, margins, and earnings.
  • 2022 sales achieved a new record of $19.1 million as Microbix continues to emphasize operational excellence and increase sales of innovative, proprietary, and branded medical devices.
  • Sales of test quality assessment products (“QAPs™”) and viral transport medium (“DxTM™”) each realized double-digit percentage increases over fiscal 2021.
  • Microbix continues to pursue growth in sales of its medical devices and expects that full-year fiscal 2023 will realize further sales growth and continuing positive net earnings.

Microbix Reports Results for Q3 Fiscal 2022

Retrieved on: 
Thursday, August 11, 2022
DXTM, Industry, GLOBE, Growth, TSX, YTD, BDC, Income, Pressure, VTM, Antigen, OTCQX, Online gambling, Semiconductor, Bank, Q3, Ay Qap

MISSISSAUGA, Ontario, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix), a life sciences innovator, manufacturer, and exporter, reports results for its third quarter and year-to-date fiscal 2022 ended June 30, 2022 (Q3 and YTD), with strong sales and continued positive net earnings, plus ongoing progress upon its strategic goal of increasing its capacity for medical devices production to thereby continue growing sales, margins, and earnings.

Key Points: 
  • MISSISSAUGA, Ontario, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix), a life sciences innovator, manufacturer, and exporter, reports results for its third quarter and year-to-date fiscal 2022 ended June 30, 2022 (Q3 and YTD), with strong sales and continued positive net earnings, plus ongoing progress upon its strategic goal of increasing its capacity for medical devices production to thereby continue growing sales, margins, and earnings.
  • Q3 revenues were $5.0 million, down 8% from Q3 2021, while YTD top-line increased 14% to $14.7 million.
  • Three Months Ending June 30, 2022 (Q3)
    Q3 revenue was $5,011,025, an 8% decrease from Q3 2021 revenues of $5,451,834.
  • Year-over-year, Q3 sales were most influenced by the timing of deliveries of DxTM, which were higher in Q3 2021.

Microbix Reports Record Results for Q2 Fiscal 2022

Retrieved on: 
Thursday, May 12, 2022
Income, TSX, Industry, Ay Qap, Antigen, BDC, VTM, Sale, Growth, OTCQX, GLOBE, Online gambling, Semiconductor, Bank, Security (finance), H1, Q2, DXTM

Q2 revenues achieved a record level of $4.9 million, up 12% from Q2 2021, as Microbix continues to emphasize operational excellence and the sale of innovative, proprietary, and branded medical devices.

Key Points: 
  • Q2 revenues achieved a record level of $4.9 million, up 12% from Q2 2021, as Microbix continues to emphasize operational excellence and the sale of innovative, proprietary, and branded medical devices.
  • Microbixs viral transport medium (branded DxTM) contributed strongly, with Q2 sales of $1.9 million versus $255,000 in Q2 2021.
  • Sales of antigens in Q2 were $1.6 million (with improved margins) and royalties were higher than Q2 2021.
  • Microbix continues to pursue growth in sales of its medical devices and expects that fiscal 2022 will realize materially-positive net earnings, as were achieved in fiscal 2021.

Microbix Invests to Further Scale Its Business

Retrieved on: 
Tuesday, March 29, 2022
Company, Medical device, Organization, TGA, U.S. FDA, Investment, OTCQX, CE, Laboratory information management system, ISO 9001, Growth, Medtech, QMS, Antigen, Enterprise resource planning, Health, TSX, Prospectus, Documentation, ISO13485, DXTM, Goal, Health Canada, GLOBE, Quality management system, Solution, News, NetSuite, ERP, FDA, Engineering, ISO9001

These initiatives will support more rapid growth in each of Microbixs business lines its test ingredients business (antigens), its test Quality Assessment Products (QAPs), and its Viral Transport Medium (DxTM).

Key Points: 
  • These initiatives will support more rapid growth in each of Microbixs business lines its test ingredients business (antigens), its test Quality Assessment Products (QAPs), and its Viral Transport Medium (DxTM).
  • Microbix currently operates a stringent, but paper-based ISO9001 and ISO13485 QMS appropriate for the highly-regulated markets in which it operates.
  • Dr. Ken Hughes, Microbixs Chief Operating Officer, commented, Our current QMS/ERP solutions have ably supported Microbix over the last several years.
  • Microbix is ISO 9001 and 13485 accredited, U.S. FDA registered, Australian TGA registered, Health Canada establishment licensed, and provides CE marked products.

Microbix Advances Commissioning of Sites Two and Three

Retrieved on: 
Tuesday, February 15, 2022
Health, OTF, Company, Solution, Economic development, Ministry of Economic Development, Job Creation and Trade, Medical device, Goal, Health Canada, QAP (Colombia), Antigen, FDA, Public health, OTCQX, Federal Economic Development Initiative for Northern Ontario, U.S. FDA, Engineering, DXTM, ISO 9001, News, TGA, Federal Economic Development Agency for Southern Ontario, CE, TSX, GLOBE, Organization

The goal of building-out and equipping these two sites is to expand production capacity for both QAPs and DxTM by five to tenfold current levels.

Key Points: 
  • The goal of building-out and equipping these two sites is to expand production capacity for both QAPs and DxTM by five to tenfold current levels.
  • For DxTM, greater production will enable Microbix to offer strategic quantities of this viral transport medium to governments and private industry buyers beyond Ontario.
  • Microbix now occupies approximately 35,000 square feet across its three adjacent sites at 235, 265 and 275 Watline Ave. in Mississauga, Ontario, Canada.
  • The majority of space within its sites is devoted to the manufacture of test kit ingredients (antigens), DxTM, and QAPs.

Microbix Receives $4.7 Million Order for Viral Transport Medium

Retrieved on: 
Friday, December 24, 2021
TSX, Goal, Virus, U.S. FDA, QAP (Colombia), CE, Medical device, COO, News, Federal, OTCQX, Engineering, VTM, Federal Economic Development Initiative for Northern Ontario, Organization, TGA, Health, Ministry of Economic Development, Job Creation and Trade, COVID-19, Solution, Antigen, OTF, Health Canada, Economic development, COVID, Company, Ministry, Laboratory, ISO 9001, Federal Economic Development Agency for Southern Ontario, GLOBE, FDA, Pharmacy, Automation, Animal, Vaccine, DXTM

MISSISSAUGA, Ontario, Dec. 24, 2021 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix), a life sciences innovator and exporter, announces receipt of a follow-on order of C$ 4.7 million for its viral transport medium (generically known as VTM and branded DxTM by Microbix).

Key Points: 
  • MISSISSAUGA, Ontario, Dec. 24, 2021 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix), a life sciences innovator and exporter, announces receipt of a follow-on order of C$ 4.7 million for its viral transport medium (generically known as VTM and branded DxTM by Microbix).
  • This entire order for DxTM is binding and is expected to result in C$ 1.75 million of revenues in the Q1 of fiscal 2022 ending 31 December, 2021.
  • The balance of the order will be delivered across Q2 and Q3 of fiscal 2022; quarters respectively ending 31 March and 30 June, 2022.
  • Microbix remains the only domestic manufacturer of VTM to Ontario and is sourcing its critical raw materials from Canada-based suppliers.

Microbix Reports Record Results for Fiscal 2021

Retrieved on: 
Thursday, December 23, 2021
TSX, DXTM, Marketing, Income, Sale, Ay Qap, OTCQX, Industry, Growth, VTM, Antigen, GLOBE, EBITDA, Animal, Security (finance), Life insurance

MISSISSAUGA, Ontario, Dec. 23, 2021 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix), a life sciences innovator and exporter, reports results for its year and fourth quarter ended September 30, 2021 (2021 and Q4), with record sales and earnings, plus progress upon its strategic goal of increasing the proportion of revenues derived from medical devices.

Key Points: 
  • MISSISSAUGA, Ontario, Dec. 23, 2021 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix), a life sciences innovator and exporter, reports results for its year and fourth quarter ended September 30, 2021 (2021 and Q4), with record sales and earnings, plus progress upon its strategic goal of increasing the proportion of revenues derived from medical devices.
  • 2021 revenues were up 77% from 2020, achieving a record level of $18.6 million as Microbix continues to emphasize operational excellence and the sale of innovative, proprietary, and branded medical devices.
  • Overall, sales achieved a favourable gross margin of 59% for fiscal 2021, in comparison to 44% in fiscal 2020 and resulted in strong EBITDA and record operating and net income.
  • Microbix continues to pursue growth in sales of its medical devices and expects that fiscal 2022 will realize positive net earnings, as for fiscal 2021.

Microbix Reports Record Results for Q3 Fiscal 2021

Retrieved on: 
Thursday, August 12, 2021
Ay Qap, GLOBE, OTCQX, Industry, EBITDA, YTD, Sale, Growth, DXTM, VTM, TSX, COVID-19, Income, Pharmaceutical industry, Bank

MISSISSAUGA, Ontario, Aug. 12, 2021 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix), a life sciences innovator and exporter, reports results for its third quarter and nine months of fiscal 2021 ending June 30, 2021 (Q3 and YTD), with record sales and earnings, plus progress upon its strategic goal of increasing the proportion of revenues derived from innovative, proprietary, and branded medical devices.

Key Points: 
  • MISSISSAUGA, Ontario, Aug. 12, 2021 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix), a life sciences innovator and exporter, reports results for its third quarter and nine months of fiscal 2021 ending June 30, 2021 (Q3 and YTD), with record sales and earnings, plus progress upon its strategic goal of increasing the proportion of revenues derived from innovative, proprietary, and branded medical devices.
  • Sales of its test quality assessment products (QAPs) for Q3 increased 84% from the same period in fiscal 2020 (Q3 2020).
  • Microbix continues to pursue growth in sales of its medical devices and expects that subsequent quarters will realize positive net earnings, as have each of Q1, Q2, and Q3 of fiscal 2021.
  • Included were antigen revenues of $2,398,068 (Q3 2020 - $2,245,912) and QAPs revenues were $1,051,618 (Q3 2020 - $570,148) for segment growth of 84%.